A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature

A new strategy of desensitization in mucopolysaccharidosis type II disease treated with idursulfase therapy: A case report and review of the literature

Mucopolysaccharidosis type II (MPS II) is a multisystemic lysosomal storage disorder caused by deficiency of the iduronate 2-sulfatase enzyme. Currently, enzyme replacement therapy (ERT) with recombinant idursulfase is the main treatment available to decrease morbidity and improve quality of life. H...

Full description

Bibliographic Details
Main Authors: Vincenza Gragnaniello, Silvia Carraro, Laura Rubert, Daniela Gueraldi, Chiara Cazzorla, Pamela Massa, Stefania Zanconato, Alberto B. Burlina
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Molecular Genetics and Metabolism Reports
Subjects:
Mucopolysaccharidosis type II
Hunter disease
Enzyme replacement therapy
Idursulfase
Infusion-associated reactions
Desensitization
Online Access:http://www.sciencedirect.com/science/article/pii/S2214426922000386

Internet

http://www.sciencedirect.com/science/article/pii/S2214426922000386

Similar Items